What is Sino Biopharmaceutical Price-to-Free-Cash-Flow?
As of today (2024-12-14), Sino Biopharmaceutical's share price is $0.424.
Sino Biopharmaceutical's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $0.04. Hence, Sino Biopharmaceutical's Price-to-Free-Cash-Flow Ratio for today is 11.16.
The historical rank and industry rank for Sino Biopharmaceutical's Price-to-Free-Cash-Flow or its related term are showing as below:
SBMFF'
s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.11 Med: 27.2 Max: 54.1
Current: 11
During the past 13 years, Sino Biopharmaceutical's highest Price-to-Free-Cash-Flow Ratio was 54.10. The lowest was 9.11. And the median was 27.20.
SBMFF's Price-to-Free-Cash-Flow is ranked better than 82.88% of 222
companies
in the Biotechnology industry
Industry Median: 35.18
vs SBMFF: 11.00
During the past 12 months, the average Free Cash Flow per Share Growth Rate of Sino Biopharmaceutical was 61.30% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 5.50% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 5.20% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was 16.10% per year.
During the past 13 years, Sino Biopharmaceutical's highest 3-Year average Free Cash Flow per Share Growth Rate was 94.60% per year. The lowest was -33.10% per year. And the median was 8.10% per year.
Sino Biopharmaceutical Price-to-Free-Cash-Flow Historical Data
The historical data trend for Sino Biopharmaceutical's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Sino Biopharmaceutical Price-to-Free-Cash-Flow Chart
Competitive Comparison of Sino Biopharmaceutical's Price-to-Free-Cash-Flow
For the Biotechnology subindustry, Sino Biopharmaceutical's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sino Biopharmaceutical's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Sino Biopharmaceutical's Price-to-Free-Cash-Flow falls into.
Sino Biopharmaceutical Price-to-Free-Cash-Flow Calculation
Sino Biopharmaceutical's Share Price of today is $0.424.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sino Biopharmaceutical's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $0.04.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Sino Biopharmaceutical (OTCPK:SBMFF) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Sino Biopharmaceutical Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Sino Biopharmaceutical's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SBMFF has been successfully added to your 